ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-ACPA"

  • Abstract Number: 0512 • ACR Convergence 2024

    Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients

    Jasmine Shwetar1, William Rigby2, Sladjana Skopelia-Gardner3, Abhimanyu Armarnani1, Kelly Ruggles1 and Gregg Silverman1, 1NYU Grossman School of Medicine, New York, NY, 2Dartmouth-Hitchcock, Norwich, VT, 3Dartmouth Hitchcock Medical Center, Hanover, NH

    Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…
  • Abstract Number: 1342 • ACR Convergence 2024

    Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population

    chandhu aS1, Josna Joseph1, ABHILASHA ARVIND MANWATKAR2 and John Mathew3, 1CMC Vellore, Vellore, Tamil Nadu, India, 2christian medical college, vellore, Tamil Nadu, India, 3Christian Medical college , Vellore , India, Vellore, India

    Background/Purpose: Rheumatoid Arthritis (RA) is an autoantibody mediated disease with deforming peripheral arthritis. Autoantibodies widely used are rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).…
  • Abstract Number: 2212 • ACR Convergence 2024

    Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort

    Rodrigo Garcia Salinas1, Felicia Almada2, Gisel Reyes-Jara2, Ronald Perez-Andocillas2 and Sebastian Magri3, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano La Plata, Melchor Romero, Argentina

    Background/Purpose: To estimate the frequency of seropositive arthralgia (SA) in a large cohort of patients evaluated for arthralgia in Reuma-check program. To compare the features…
  • Abstract Number: 0389 • ACR Convergence 2023

    The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms

    Andrea Di Matteo1, Kulveer Mankia2, Leticia Garcia-Montoya2, Jacqueline Nam2, Sana sharrack3, Michael Mahler4 and Paul Emery3, 1Polytechnic University of Marche, Jesi, Italy, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Werfen, San Diego, CA

    Background/Purpose: To investigate, in primary care, whether testing anti-CCP3 antibodies in anti-CCP2 negative individuals with musculoskeletal (MSK) symptoms, improved the prediction of inflammatory arthritis (IA)/rheumatoid…
  • Abstract Number: 1271 • ACR Convergence 2023

    Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

    Bong-Ki Hong1, Sungyong You2, Naeun Lee1, Jung Gon Kim3, Kijun Lee4, Ji Hyeon Ju5, Wan-Uk Kim1 and Ho-Youn Kim6, 1The Catholic University of Korea, Seoul, South Korea, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Inje University Ilsan Paik Hospital, Goyang, South Korea, 4YiPSCELL, Secho, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea

    Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
  • Abstract Number: 1739 • ACR Convergence 2023

    Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies

    Khetam Ghannam1, Marieluise Kirchner2, Holger Bang3, Thomas Häupl4, Sarah Ohrndorf1, Jan Zernicke1, Ulrike Kuckelkorn5, Philipp Mertins6, Eugen Feist7 and Gerd Burmester8, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 3Orgentec Diagnostika GmbH, Mainz, Germany, 4Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 5Institute of Biochemistry, Berlin, Germany, 6Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 7Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 8Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
  • Abstract Number: 1743 • ACR Convergence 2023

    Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies

    Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle3, kevin Deane3, Michael Holer3 and kristine Kuhn2, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
  • Abstract Number: 2121 • ACR Convergence 2023

    Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

    Takao Fujii, Katsunori Tanaka, Ryo Matsumiya, Kayoko Tabata and Shigeru Iwata, Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan

    Background/Purpose: Anti-cyclic citrullinated peptide antibody (anti-CCP Ab) positivity is closely associated with bone destruction in rheumatoid arthritis (RA) patients, but the correlation between the Ab…
  • Abstract Number: 0530 • ACR Convergence 2022

    Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

    Juergen Rech1, Arnd Kleyer2, Mikkel Østergaard3, Melanie Hagen2, Larissa Valor Mendez2, Koray Tascilar2, Gerhard Kroenke2, Verena Schönau2, David Simon2, stefan Kleinert4, Xenofon Baraliakos5, Juergen Braun6, Axel Hueber7, Martin Fleck8, Andrea Rubbert-Roth9, Frank Behrens10, Martin Feuchtenberger11, M. Zaenker12, Reinhard Voll13, Cornelia Glaser14, Mária Filková15, Eugen Feist16, Gerd Burmester17, Kirsten Karberg18, Johannes Strunk19, Juan Canete20, Ladislav Šenolt15, Esperanza Naredo21 and Georg Schett22, 1University Clinic Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Rigshospitalet, University of Copenhagen, Glostrup, Denmark, 4Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 5Ruhr University Bochum, Department of Rheumatology, Bochum, Germany; Rheumazentrum Ruhrgebiet, Rheumazentrum Ruhrgebiet, Herne, Germany, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Klinikum Nuernberg Nord, Abteilung fuer Rheumatologie, Nuernberg, Germany, 8Asklepios Klinikum Bad Abbach, Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, 9Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 10Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, 11MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, 12Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, 13Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg im Breisgau, Germany, 14Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 15Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 16Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, 17Charité University Medicine Berlin, Berlin, Germany, 18Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, 19Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Koeln, Germany, 20Unidad de Artritis Hospital Clinic, Barcelona, Spain, 21Hospital General Universitario Gregorio Marañón and Complutense University, Madrid, Spain, 22Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA),…
  • Abstract Number: 0766 • ACR Convergence 2022

    CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients

    Nilasha Ghosh1, Diviya Rajesh1, Jessica Kirschmann2, Deanna Jannat-Khah, DrPH, MSPH1, Karmela Kim Chan1, Susan Goodman1, Vivian Bykerk1, William Robinson3 and Anne Bass4, 1Hospital for Special Surgery, New York, NY, 2Stanford University, Stanford, CA, 3Stanford University School of Medicine, Palo Alto, CA, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICI) have markedly improved the treatment of many advanced cancers; however, they can result in immune-related adverse events (irAE) including ICI-inflammatory…
  • Abstract Number: 0910 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies

    Albert Pérez-Isidro1, Raul Castellanos-Moreira1, Juan Camilo Sarmiento-Monroy2, Noemi de Moner1, Maresa Grundhuber3, Odette Vinas1, Raimon Sanmarti2 and Estibaliz Ruiz-Ortiz1, 1Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Thermo Fisher Scientific, Freiburg, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
  • Abstract Number: 0938 • ACR Convergence 2022

    Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up

    Antonio Manzo1, Emanuele Bozzalla Cassione2, Iolanda Mazzucchelli3, Silvia Grignaschi3, Blerina Xoxi3, Terenzj Luvaro3, Ludovico De Stefano3, Garifallia Sakellariou3, SERENA BUGATTI3 and Carlomaurizio Montecucco4, 1IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy, 2University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, 3University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, 4Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy

    Background/Purpose: Early diagnosis and treat-to-target strategies with synthetic conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of…
  • Abstract Number: 1230 • ACR Convergence 2021

    Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study

    Andrea Rubbert-Roth1, Jeffrey Sparks2, Arnaud Constantin3, Ricardo Xavier4, Yanna Song5, Jessica Suboticki5 and Roy Fleischmann6, 1Kantonspital St Gallen, St.Gallen, Switzerland, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3Toulouse University Hospital, Toulouse Cedex 9, France, 4Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5AbbVie Inc., North Chicago, IL, 6University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
  • Abstract Number: 1753 • ACR Convergence 2020

    Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention

    Sara Eileen Meyer1, Julianna Rachel Hoeper2, Kirsten Hoeper1, Torsten Witte3 and Dirk Meyer-Olson4, 1Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, 2Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, 3Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, 4Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…
  • Abstract Number: 2006 • ACR Convergence 2020

    Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    Markus Rehberg1, Clemens Giegerich1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Jeffrey R Curtis4, Jacques-Eric Gottenberg5, Andreas Schwarting6, Santos Castañeda7, Andrea Rubbert Roth8 and Ernest Choy9, 1Sanofi, Frankfurt, Germany, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Strasbourg University Hospital, Strasbourg, France, 6Johannes Gutenberg University, Mainz, Germany, 7Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 8Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 9CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology